Metastatic spinal cord compression: diagnosis and management of adults at risk of and with metastatic spinal cord compression Clinical Guideline CG75(26th November 2008)
The advice in the NICE guideline covers: adults who have, or are at risk of developing, metastatic spinal cord compression because they have cancer elsewhere in their body that has spread to their spine. It does not specifically look at: children, or adults whose cancer started in the spine or who have compression of the spinal cord that is not caused by cancer.
NICE Guideline
Full Guideline
Quick Reference Guide
Understanding NICE Guidance
Costing Report
Costing Template
Local Patient Information Template
Erlotinib for the treatment of non-small cell lung cancer Technology Appraisal TA162 (26th November 2008)
Erlotinib is recommended as an alternative to docetaxel for patients with non-small-cell lung cancer (NSCLC) who have already tried one chemotherapy regimen but it has not worked. Erlotinib should be used only when the manufacturer provides the drug at the same overall treatment cost as docetaxel. This cost includes the cost of giving the drug, treatments for any side effects and the cost of monitoring patients to check that treatment is working.
Guidance
Quick Reference Guide
Understanding NICE Guidance
Audit Support
Costing Statement
Electrically-stimulated intravesical chemotherapy for superficial bladder cancer Interventional Procedure IPG 277 (26th November 2008)
This procedure, also known as electromotive drug administration (EMDA) of intravesical chemotherapy, can be used for patients with bladder cancer, either before or after surgery. A solution including a chemotherapy drug is injected into the bladder using a thin tube inserted through the urethra. At the same time, an electrode is inserted in the bladder and other electrodes are placed on the skin of the lower abdomen. An electric current is then created with the aim of improving absorption of the chemotherapeutic drugs.
Guidance
Understanding NICE Guidance
Consultation Comments
Laparoscopic prostatectomy for benign prostatic obstruction Interventional Procedure IPG275 (26th November 2008)
The prostate gland lies just under a man's bladder. Benign prostatic obstruction (BPO) happens when the prostate gland gets bigger, squeezing the tube that carries urine from the bladder to the tip of the penis (the urethra) and causing problems with passing of urine. Laparoscopic prostatectomy involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (also known as 'keyhole surgery').
Guidance
Understanding NICE Guidance
Consultation Comments
Transabdominal artificial bowel sphincter implantation for faecal incontinence Interventional Procedure IPG275 (26th November 2008)
Faecal incontinence occurs when a person loses the ability to control their bowel movements, resulting in leakage of faeces. It can happen as a result of congenital abnormalities of the anal sphincter (the ring of muscle that keeps the anus closed), injury to the sphincter during childbirth or surgery, disease of the nervous system, prolapse of the pelvic organs or pelvic radiotherapy. In this procedure, an inflatable circular cuff is placed in the anorectal area. The cuff is controlled using a pump that is implanted under the skin in the lower half of the abdomen and connected to a reservoir of fluid. Pressure on the pump allows fluid to move to and from the cuff, to open or close the anus and allow bowel movements to be controlled.
Guidance
Understanding NICE Guidance
Audit Support
Review of the single and multiple technology appraisal processes (3rd December 2008)
NICE has undertaken a review of the guides to the single and multiple technology appraisal processes. The new draft guides are now open for consultation. Closing date for comments is 3rd March 2009.
Review
Review of the specification for manufacturer sponsor submission of evidence (3rd December 2008)
NICE has undertaken a review of the Specification for Manufacturer/Sponsor Submission of Evidence. The original specification was issued in May 2006 and an update was issued in July 2008. The new draft Specification for Manufacturer/Sponsor Submission of Evidence is now open for consultation. Closing date for comments is 3rd March 2009.
Review
Influenza - zanamivir, amantadine and oseltamivir (review): final appraisal determination (FAD) (8th December 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58) and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. The appeal period will close on 9th January 2009.
FAD
Response to consultee and commentator comments
Additional scenario analyses
Consultee and commentator comments
The advice in the NICE guideline covers: adults who have, or are at risk of developing, metastatic spinal cord compression because they have cancer elsewhere in their body that has spread to their spine. It does not specifically look at: children, or adults whose cancer started in the spine or who have compression of the spinal cord that is not caused by cancer.
NICE Guideline
Full Guideline
Quick Reference Guide
Understanding NICE Guidance
Costing Report
Costing Template
Local Patient Information Template
Erlotinib for the treatment of non-small cell lung cancer Technology Appraisal TA162 (26th November 2008)
Erlotinib is recommended as an alternative to docetaxel for patients with non-small-cell lung cancer (NSCLC) who have already tried one chemotherapy regimen but it has not worked. Erlotinib should be used only when the manufacturer provides the drug at the same overall treatment cost as docetaxel. This cost includes the cost of giving the drug, treatments for any side effects and the cost of monitoring patients to check that treatment is working.
Guidance
Quick Reference Guide
Understanding NICE Guidance
Audit Support
Costing Statement
Electrically-stimulated intravesical chemotherapy for superficial bladder cancer Interventional Procedure IPG 277 (26th November 2008)
This procedure, also known as electromotive drug administration (EMDA) of intravesical chemotherapy, can be used for patients with bladder cancer, either before or after surgery. A solution including a chemotherapy drug is injected into the bladder using a thin tube inserted through the urethra. At the same time, an electrode is inserted in the bladder and other electrodes are placed on the skin of the lower abdomen. An electric current is then created with the aim of improving absorption of the chemotherapeutic drugs.
Guidance
Understanding NICE Guidance
Consultation Comments
Laparoscopic prostatectomy for benign prostatic obstruction Interventional Procedure IPG275 (26th November 2008)
The prostate gland lies just under a man's bladder. Benign prostatic obstruction (BPO) happens when the prostate gland gets bigger, squeezing the tube that carries urine from the bladder to the tip of the penis (the urethra) and causing problems with passing of urine. Laparoscopic prostatectomy involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (also known as 'keyhole surgery').
Guidance
Understanding NICE Guidance
Consultation Comments
Transabdominal artificial bowel sphincter implantation for faecal incontinence Interventional Procedure IPG275 (26th November 2008)
Faecal incontinence occurs when a person loses the ability to control their bowel movements, resulting in leakage of faeces. It can happen as a result of congenital abnormalities of the anal sphincter (the ring of muscle that keeps the anus closed), injury to the sphincter during childbirth or surgery, disease of the nervous system, prolapse of the pelvic organs or pelvic radiotherapy. In this procedure, an inflatable circular cuff is placed in the anorectal area. The cuff is controlled using a pump that is implanted under the skin in the lower half of the abdomen and connected to a reservoir of fluid. Pressure on the pump allows fluid to move to and from the cuff, to open or close the anus and allow bowel movements to be controlled.
Guidance
Understanding NICE Guidance
Audit Support
Review of the single and multiple technology appraisal processes (3rd December 2008)
NICE has undertaken a review of the guides to the single and multiple technology appraisal processes. The new draft guides are now open for consultation. Closing date for comments is 3rd March 2009.
Review
Review of the specification for manufacturer sponsor submission of evidence (3rd December 2008)
NICE has undertaken a review of the Specification for Manufacturer/Sponsor Submission of Evidence. The original specification was issued in May 2006 and an update was issued in July 2008. The new draft Specification for Manufacturer/Sponsor Submission of Evidence is now open for consultation. Closing date for comments is 3rd March 2009.
Review
Influenza - zanamivir, amantadine and oseltamivir (review): final appraisal determination (FAD) (8th December 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58) and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. The appeal period will close on 9th January 2009.
FAD
Response to consultee and commentator comments
Additional scenario analyses
Consultee and commentator comments
No comments:
Post a Comment